Comparator Drug vs Reference Listed Drug: Key Differences Explained

In regulatory and development discussions, the terms “comparator drug” and “Reference Listed Drug (RLD)” are sometimes used interchangeably. While they are closely related, they are not always identical in regulatory meaning.

Clarifying the distinction helps avoid misalignment during bioequivalence planning, documentation preparation, and global development strategy.

What Is a Comparator Drug?

A comparator drug is the product against which a test product is compared in a study. The comparison may be conducted to assess:

• Bioequivalence
• Dissolution similarity
• Clinical performance
• Relative pharmacokinetics

The term “comparator” is functional. It describes the role the product plays in the study, rather than its regulatory designation.

What Is a Reference Listed Drug (RLD)?

An RLD is a comparator with a specific regulatory designation. It is identified by the relevant authority as the reference standard for demonstrating equivalence in an abbreviated pathway.

All RLDs function as comparators in bioequivalence studies. However, not all comparators are formally designated RLDs.

This distinction becomes particularly relevant in multi-jurisdictional programs.

When Are Comparator and RLD the Same?

In many U.S.-focused ANDA submissions, the comparator used in the BE study is the FDA-designated RLD. In such cases, the functional and regulatory roles align.

The product is:

• The designated regulatory reference
• The physical product used in the study
• The benchmark cited in the submission

In this scenario, the terms are often used interchangeably in informal discussion, though precise terminology remains important in formal documentation.

When Can They Differ?

In global development programs, sponsors may select comparators based on the expectations of the target submission market.

For Example:

• A study conducted for one region may use a locally sourced comparator aligned with that market’s regulatory framework.
• A development program targeting multiple jurisdictions may need to consider whether the selected comparator aligns with each authority’s reference expectations.

In such cases, the comparator used in a study may not correspond to the RLD designation in another jurisdiction.

This is why regulatory planning typically addresses:

• Target submission market
• Reference product designation in that market
• Study design alignment

Why the Distinction Matters

The distinction between comparator and RLD matters for several reasons:

1. Regulatory clarity: Submissions must clearly identify the designated reference product.
2. Study validity: The comparator selected must align with regulatory expectations.
3. Documentation consistency: The product referenced in the submission must correspond to the product used in studies.

Misalignment can introduce regulatory questions during review.

Implications for Sourcing and Traceability

Whether a product is described as a comparator or an RLD, development programs typically prioritize:

• Confirmed product identity
• Batch and expiry transparency
• Storage and handling integrity
• Traceability from origin to study use

Where a product carries formal RLD designation, additional care is often taken to ensure consistency between designation and physical supply.

Key Takeaways

• A comparator drug is any product used as a reference in a study.
• An RLD is a comparator with formal regulatory designation.
• All RLDs function as comparators, but not all comparators are RLDs.
• Terminology precision supports regulatory clarity.
• Alignment between comparator selection and regulatory expectations is a standard consideration in generic development.

Clear use of terminology reflects regulatory literacy and reduces ambiguity during development and submission processes.